December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.
Genmab cans its antibody-drug conjugate against Axl kinase, an approach on which Bergenbio has gone all in.
Survival data with bemarituzumab see the company erase half of the past three years’ losses.
Merck's move on a target that has attracted little attention – Liv-1 – means future data readouts are now eagerly awaited.
All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.
The UK big pharma is set to hand Japan’s Daiichi $1bn for rights to a second antibody-drug conjugate. Immunomedics watch out.
Roche must believe that Blueprint Medicines’ Ret inhibitor pralsetinib has a safety edge over Lilly’s Retevmo.